UK DRI and Eisai, one of the world's leading research-based pharmaceutical companies, have joined forces to launch a post-doctoral research programme on dementia. This programme will be an active collaboration between the UK DRI and Eisai, who will play an ongoing, active role in the projects and will seek to work with the PIs in adding value wherever possible. For further details see Appendix 1.
Awards of up to £221,000 (direct costs) will be provided to support a new three-year postdoctoral position, including salary, and up to £20,000 per annum for reagents or other expenses (standard UK DRI centre overheads will be added to the final award amount).
Up to three awards will be made for this cycle.
We invite novel research proposals in the field of neurodegeneration that may ultimately lead to transformative medicines for dementia patients.
The overriding aim of the programme is to better understand the underlying biology that may lead to:
- The identification of new molecular targets, pathways and/or mechanisms for therapeutic intervention.
- Innovative drug methodologies to target the above (such as mechanisms for improved brain delivery, novel chemical or biological entities, cellular or genetic approaches).
- The development of novel in vitro or in vivo model systems (including cutting edge screening platforms/technologies) translatable to human biological processes, with which to investigate modulation of the above.
- The development of biomarkers for patient selection/stratification or pharmacodynamic assessment of new therapeutics.
The applicant must satisfy the selection committee that they have ready access to all necessary research facilities, samples, reagents and equipment, and have all necessary regulatory approvals such that the work can start promptly.
Proposals will be assessed, and funding decisions made by a joint UK DRI and Eisai committee. Successful applicants and their supported post-doctoral researcher will be required to attend an annual one-day workshop to discuss the ongoing work.